Clinical and subclinical ACTH-independent macronodular adrenal hyperplasia and aberrant hormone receptors.
ACTH-independent macronodular adrenal hyperplasia (AIMAH) is a very rare cause of endogenous Cushing's syndrome (CS). In this review, the clinical characteristics, the pathophysiology, and the management of AIMAH are described. AIMAH typically presents with overt CS, but subclinical oversecretion of cortisol has been increasingly described. The diagnosis is suspected by adrenal nodular enlargement on conventional imaging following the demonstration of ACTH-independent hypercortisolism. Final diagnosis is established by histological examination of the adrenal tissue. Bilateral adrenalectomy is the treatment of choice but unilateral adrenalectomy has been proposed in selected cases. In patients with subclinical CS, the decision to treat should be individualized. The pathophysiology of this condition has begun to be elucidated in recent years. Diverse aberrant membrane-bound receptors expressed in a non-mutated form in the adrenal gland have been found to be implicated in the regulation of steroidogenesis in AIMAH. When systematically screened, most patients with AIMAH and CS or subclinical CS exhibit an in vivo aberrant cortisol response to one or various ligands suggesting the presence of aberrant adrenal receptors. A protocol designed to screen patients for the presence of these aberrant receptors should be undertaken in all patients with AIMAH. The identification of these receptors provides the potential for novel pharmacological therapies by suppressing the endogenous ligands or blocking the receptor with specific antagonists.
Christopoulos
Stavroula
S
Division of Endocrinology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
Bourdeau
Isabelle
I
Lacroix
André
A
D000307:Adrenal Gland Diseases / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D000311:Adrenal Glands / Q000473:pathology*; D000315:Adrenalectomy; D000324:Adrenocorticotropic Hormone / Q000502:physiology*; D003480:Cushing Syndrome / Q000209:etiology; D006801:Humans; D006965:Hyperplasia / Q000150:complications*; D011943:Receptors, Adrenergic, beta / Q000502:physiology; D011964:Receptors, Gastrointestinal Hormone / Q000502:physiology; D018013:Receptors, Neuropeptide / Q000502:physiology*; D017483:Receptors, Vasopressin / Q000502:physiology
D011943:Receptors, Adrenergic, beta; D011964:Receptors, Gastrointestinal Hormone; D018013:Receptors, Neuropeptide; D017483:Receptors, Vasopressin; D000324:Adrenocorticotropic Hormone; C041086:gastric inhibitory polypeptide receptor